Lowell Sears Overview
- Investor Type
-
Angel
Lowell Sears General Information
Description
Mr. Lowell Sears serves as Chairman, Chief Executive Officer and Chief Investment Officer at Sears Capital Management. He serves as Board Member at SiteOne Therapeutics. He served as Board Member at Halcyon Medical. Previously, he served as Chairman at SiteOne Therapeutics. He also serves as a Board Member at Vital Therapies. He has served on the board of directors of Cellerant Therapeutics, Inc., a clinical stage biotechnology company focused on the regulation of the hematopoietic, or blood-forming, system, since February 2012 and has been Chairman of the Board since June 2012. Mr. Sears has also served on the board of directors of SymBio Pharmaceuticals, KK, Ltd., a biotechnology company that is engaged in identifying and developing therapeutics for the treatment of leukemia, multiple myeloma and lymphoma, since September 2005. From 1986 until 1994, Mr. Sears was a part of the senior management team of Amgen, Inc., a developer and manufacturer of therapeutics targeting cancers, kidney ailments, inflammatory disorders, and metabolic diseases, where he was Chief Financial Officer as well as the Senior Vice President responsible for the Asia Pacific Region. Prior to joining Amgen, Mr. Sears held senior planning and financial positions with Atlantic Richfield Company, an oil company from 1976 until 1986, including Chief Financial Officer for its Ventures Division. He earned a B.A. in economics from Claremont McKenna College and an M.B.A. from the Stanford University Graduate School of Business.
Business Details
Primary Investor Type
Corporate Office
- 20370 Town Center Lane
- Suite 120
- Cupertino, CA 95014
- United States
Lowell Sears Investments by Industry, Year, and Region
Lowell Sears FAQs
-
Who is Lowell Sears?
Lowell Sears is an angel Investor who has made 0 investments.
-
What kind of investor is Lowell Sears?
Lowell Sears is an angel investor.
-
What does Lowell Sears do?
As an angel investor, Lowell Sears invests personal money into promising companies, typically in exchange for equity.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »